Skip to content

Cognition and Magnetic Resonance Imaging of Brain Inflammation in Obesity

Neuroinflammation in Obesity

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04116229
Acronym
NIFOB
Enrollment
20
Registered
2019-10-04
Start date
2019-03-19
Completion date
2020-10-30
Last updated
2023-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Obesity, Inflammation, Cognitive impairment, Neuroimaging, Magnetic resonance imaging

Brief summary

The rate of obesity in the United States is high and is a risk factor for concurrent cognitive impairment and, in late life, dementias such as Alzheimer's disease. In order to prevent or reduce cognitive impairment, the mechanism underlying the link between obesity and cognitive impairment must be understood. The current study aims to provide preliminary data on whether brain inflammation occurs in obesity and relates to cognitive deficits using magnetic resonance neuroimaging and cognitive testing. It is hypothesized that obese individuals will have greater brain inflammation and lower cognitive function compared to normal-weight individuals. Further, it is predicted that brain inflammation will relate to cognitive function and plasma indicators of inflammation in obese individuals.

Detailed description

Initially, normal-weight or obese potential participants are screened by a phone interview that assesses medical history. Obtainment of informed consent and further screening occurs on the day of the study visit. Participants then undergo a 2 hour oral glucose tolerance test (OGTT) including blood draws for metabolic and inflammatory marker levels in plasma. Lunch is then provided. Participants are then administered 30 minute computer-based cognitive testing from the NIH Toolbox Cognition Battery. After cognitive testing, participants undergo 1.5 hour magnetic resonance imaging (MRI) that includes structural, diffusion tensor, and functional MR imaging.

Interventions

PROCEDUREOral glucose tolerance test

After 8 hours fasting overnight, an intravenous catheter is placed in the arm or hand for blood draws. Participants drink 75 grams of an oral glucose drink after baseline blood samples are drawn. More blood draws occur at 10, 20, 30, 60 and 120 min post-glucose drink.

BEHAVIORALCognitive testing

For approximately 40 minutes, participants are assessed for cognitive function using computer-based tests available from the NIH Toolbox Cognitive Battery (Weintraub et al., 2013), including attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall.

PROCEDUREMagnetic resonance imaging

Magnetic resonance imaging (MRI) scans will be performed in a 3 Tesla MRI scanner over 1.5 hours. Participants will be asked to lay down flat on their backs and to try to stay still throughout the MRI scan. The participant will wear MRI-safe headphones to block out noise due to the MRI scans. Participant comfort will be verbally checked on throughout the scan and the participant will be provided with a 'squeeze ball' to signal the MRI technician that they want to get out of the scanner immediately.

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
Washington University School of Medicine
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

Neuroimaging data was processed using automated methods blind to group membership. Blood samples were analyzed by laboratory personnel blind to group membership.

Intervention model description

This study employed a single group model in which participants with obesity and participants with normal-weight underwent magnetic resonance imaging, blood draws and cognitive assessment.

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Non-obese (body mass index = 18 - 25 kg/m\^2) or Obese (body mass index ≥ 30 kg/m\^2 * Any race or ethnicity * Native English speaker

Exclusion criteria

* Past or current diabetes * Current psychotropic medication use * Past or current neurological illness * Past or current substance or alcohol misuse * Past or current mental illness * Current binge eating disorder * Magnetic resonance imaging contraindications * Pregnancy * Currently lactating * Tobacco use within past month * Over 350 lb

Design outcomes

Primary

MeasureTime frameDescription
Brain Inflammation Metrics in Obese and Normal-weight Individuals as Measured by Magnetic Resonance Image-based Diffusion Basis Spectrum Imaging (DBSI)1.5 hours at the end of one (up to) 8 hour study day that includes all outcome measuresDiffusion Basis Spectrum Imaging (Cross and Song, 2017) is a computational method that will be applied to diffusion tensor images of the brain to estimate putative inflammation-related markers including cellularity and edema in obese and normal-weight individuals. DBSI metrics are quantitative but unitless. Cellularity and edema fractions of the total diffusion signal (including axial, radial, restricted (cellularity) and hindered (edema)) will be estimated in brain white matter tracts.
Cognitive Function in Obese and Normal-weight Individuals as Measured by the National Institutes of Health (NIH) Toolbox Cognitive Battery and DBSI Putative Neuroinflammation Metrics40 minutes during one (up to) 8 hour study day that includes all outcome measures; after OGTT and prior to MRICognitive performance including fluid and crystallized cognition composite T-scores from computer-based NIH Cognitive Toolbox assessments (Weintraub et al., 2013) will be assessed in obese and normal-weight individuals. These T-scores will include scores from tasks that assess attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall (see NIH Toolbox Cognitive Battery website). T-scores are corrected for socioeconomic status and their distribution has a mean of 50 and a standard deviation of 10. Higher T-scores indicate better cognitive function. T-scores will be correlated with DBSI-assessed neuroinflammation metrics including restricted fraction (DBSI RF, putative cellularity) and hindered fraction (DBSI HF, putative vasogenic edema) in brain white matter tracts.

Countries

United States

Participant flow

Participants by arm

ArmCount
Normal-weight
Participants who have a body mass index within the normal-weight category. Oral glucose tolerance test: After 8 hours fasting overnight, an intravenous catheter is placed in the arm or hand for blood draws. Participants drink 75 grams of an oral glucose drink after baseline blood samples are drawn. More blood draws occur at 10, 20, 30, 60 and 120 min post-glucose drink. Cognitive testing: For approximately 40 minutes, participants are assessed for cognitive function using computer-based tests available from the NIH Toolbox Cognitive Battery (Weintraub et al., 2013), including attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall. Magnetic resonance imaging: Magnetic resonance imaging (MRI) scans will be performed in a 3 Tesla MRI scanner over 1.5 hours. Participants will be asked to lay down flat on their backs and to try to stay still throughout the MRI scan. The participant will wear MRI-safe headphones to block out noise due to the MRI scans. Participant comfort will be verbally checked on throughout the scan and the participant will be provided with a 'squeeze ball' to signal the MRI technician that they want to get out of the scanner immediately.
8
Obese
Participants who have a body mass index within the obese category. Oral glucose tolerance test: After 8 hours fasting overnight, an intravenous catheter is placed in the arm or hand for blood draws. Participants drink 75 grams of an oral glucose drink after baseline blood samples are drawn. More blood draws occur at 10, 20, 30, 60 and 120 min post-glucose drink. Cognitive testing: For approximately 40 minutes, participants are assessed for cognitive function using computer-based tests available from the NIH Toolbox Cognitive Battery (Weintraub et al., 2013), including attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall. Magnetic resonance imaging: Magnetic resonance imaging (MRI) scans will be performed in a 3 Tesla MRI scanner over 1.5 hours. Participants will be asked to lay down flat on their backs and to try to stay still throughout the MRI scan. The participant will wear MRI-safe headphones to block out noise due to the MRI scans. Participant comfort will be verbally checked on throughout the scan and the participant will be provided with a 'squeeze ball' to signal the MRI technician that they want to get out of the scanner immediately.
6
Total14

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyMet exclusion criteria during screeneing on day of study visit.23
Overall StudyScheduling not possible.01

Baseline characteristics

CharacteristicNormal-weightObeseTotal
Age, Continuous34.9 years
STANDARD_DEVIATION 6.6
36.5 years
STANDARD_DEVIATION 6.8
35.6 years
STANDARD_DEVIATION 6.5
Body Mass Index22.4 kg/m^2
STANDARD_DEVIATION 1.5
37.3 kg/m^2
STANDARD_DEVIATION 4.5
28.7 kg/m^2
STANDARD_DEVIATION 8.2
Fasting glucose87.0 mg/dL
STANDARD_DEVIATION 4.6
87.2 mg/dL
STANDARD_DEVIATION 8
87.0 mg/dL
STANDARD_DEVIATION 6
Fasting plasma adiponectin11.3 ug/mL
STANDARD_DEVIATION 5.6
10.8 ug/mL
STANDARD_DEVIATION 4.9
11.1 ug/mL
STANDARD_DEVIATION 5.1
Fasting plasma C-reactive protein (CRP)1.02 mg/L
STANDARD_DEVIATION 0.8
4.84 mg/L
STANDARD_DEVIATION 3.1
2.66 mg/L
STANDARD_DEVIATION 2.8
Fasting plasma free fatty acid (FFA)0.61 mEq/L
STANDARD_DEVIATION 0.27
0.81 mEq/L
STANDARD_DEVIATION 0.29
0.7 mEq/L
STANDARD_DEVIATION 0.29
Fasting plasma ghrelin1498.5 pg/mL
STANDARD_DEVIATION 568.6
914.8 pg/mL
STANDARD_DEVIATION 261.7
1248.4 pg/mL
STANDARD_DEVIATION 538.8
Fasting plasma insulin5.28 uU/mL
STANDARD_DEVIATION 3.73
15.62 uU/mL
STANDARD_DEVIATION 10.82
9.71 uU/mL
STANDARD_DEVIATION 9
Fasting plasma interleukin-10 (IL-10)1.85 pg/mL
STANDARD_DEVIATION 1.38
1.97 pg/mL
STANDARD_DEVIATION 0.75
1.9 pg/mL
STANDARD_DEVIATION 1.12
Fasting plasma leptin19.9 ug/L
STANDARD_DEVIATION 13.4
110 ug/L
STANDARD_DEVIATION 49.7
58.5 ug/L
STANDARD_DEVIATION 56.4
Fasting plasma monocyte chemoattractant protein-1 (MCP-1)140.9 pg/mL
STANDARD_DEVIATION 37
160.3 pg/mL
STANDARD_DEVIATION 40.1
149.2 pg/mL
STANDARD_DEVIATION 38.2
Fasting plasma tumor necrosis factor-alpha (TNF-alpha)0.69 pg/mL
STANDARD_DEVIATION 0.16
0.84 pg/mL
STANDARD_DEVIATION 0.16
0.75 pg/mL
STANDARD_DEVIATION 0.17
HbA1c5.1 percentage of glycosylated hemoglobin
STANDARD_DEVIATION 0.1
5.1 percentage of glycosylated hemoglobin
STANDARD_DEVIATION 0.4
5.1 percentage of glycosylated hemoglobin
STANDARD_DEVIATION 0.2
Homeostatic measure of insulin resistance (HOMA-IR)1.21 unitless
STANDARD_DEVIATION 0.79
3.47 unitless
STANDARD_DEVIATION 2.56
2.18 unitless
STANDARD_DEVIATION 2.05
Race/Ethnicity, Customized
Asian, non-Hispanic
1 Participants0 Participants1 Participants
Race/Ethnicity, Customized
Black, non-Hispanic
1 Participants2 Participants3 Participants
Race/Ethnicity, Customized
White, non-Hispanic
6 Participants4 Participants10 Participants
Region of Enrollment
United States
8 participants6 participants14 participants
Sex: Female, Male
Female
6 Participants5 Participants11 Participants
Sex: Female, Male
Male
2 Participants1 Participants3 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 80 / 6
other
Total, other adverse events
0 / 80 / 6
serious
Total, serious adverse events
0 / 80 / 6

Outcome results

Primary

Brain Inflammation Metrics in Obese and Normal-weight Individuals as Measured by Magnetic Resonance Image-based Diffusion Basis Spectrum Imaging (DBSI)

Diffusion Basis Spectrum Imaging (Cross and Song, 2017) is a computational method that will be applied to diffusion tensor images of the brain to estimate putative inflammation-related markers including cellularity and edema in obese and normal-weight individuals. DBSI metrics are quantitative but unitless. Cellularity and edema fractions of the total diffusion signal (including axial, radial, restricted (cellularity) and hindered (edema)) will be estimated in brain white matter tracts.

Time frame: 1.5 hours at the end of one (up to) 8 hour study day that includes all outcome measures

Population: Data from 8 individuals with normal-weight and 6 individuals with obesity were included in baseline analyses. Five individuals were enrolled in the study but their data was not collected due to meeting exclusion criteria. One individual was enrolled but could not be scheduled for the study and therefore did not contribute data.

ArmMeasureGroupValue (MEAN)Dispersion
Normal-weightBrain Inflammation Metrics in Obese and Normal-weight Individuals as Measured by Magnetic Resonance Image-based Diffusion Basis Spectrum Imaging (DBSI)DBSI restricted fraction (cellularity).0468 unitlessStandard Deviation 0.0024
Normal-weightBrain Inflammation Metrics in Obese and Normal-weight Individuals as Measured by Magnetic Resonance Image-based Diffusion Basis Spectrum Imaging (DBSI)DBSI hindered fraction (vasogenic edema).176 unitlessStandard Deviation 0.013
ObeseBrain Inflammation Metrics in Obese and Normal-weight Individuals as Measured by Magnetic Resonance Image-based Diffusion Basis Spectrum Imaging (DBSI)DBSI hindered fraction (vasogenic edema).186 unitlessStandard Deviation 0.014
ObeseBrain Inflammation Metrics in Obese and Normal-weight Individuals as Measured by Magnetic Resonance Image-based Diffusion Basis Spectrum Imaging (DBSI)DBSI restricted fraction (cellularity).0492 unitlessStandard Deviation 0.0034
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study.p-value: 0.28Independent-Samples Median Test
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study.p-value: 0.03Independent-Samples Median Test
Primary

Cognitive Function in Obese and Normal-weight Individuals as Measured by the National Institutes of Health (NIH) Toolbox Cognitive Battery and DBSI Putative Neuroinflammation Metrics

Cognitive performance including fluid and crystallized cognition composite T-scores from computer-based NIH Cognitive Toolbox assessments (Weintraub et al., 2013) will be assessed in obese and normal-weight individuals. These T-scores will include scores from tasks that assess attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall (see NIH Toolbox Cognitive Battery website). T-scores are corrected for socioeconomic status and their distribution has a mean of 50 and a standard deviation of 10. Higher T-scores indicate better cognitive function. T-scores will be correlated with DBSI-assessed neuroinflammation metrics including restricted fraction (DBSI RF, putative cellularity) and hindered fraction (DBSI HF, putative vasogenic edema) in brain white matter tracts.

Time frame: 40 minutes during one (up to) 8 hour study day that includes all outcome measures; after OGTT and prior to MRI

Population: Two individuals in the normal-weight group were not native English speakers and their cognitive data is not included. A complete set of fluid cognition measures was not collected from one normal-weight participant and their fluid cognition data is not included.

ArmMeasureGroupValue (MEAN)Dispersion
Normal-weightCognitive Function in Obese and Normal-weight Individuals as Measured by the National Institutes of Health (NIH) Toolbox Cognitive Battery and DBSI Putative Neuroinflammation MetricsCrystallized Cognition60.3 T-scoreStandard Deviation 6.9
Normal-weightCognitive Function in Obese and Normal-weight Individuals as Measured by the National Institutes of Health (NIH) Toolbox Cognitive Battery and DBSI Putative Neuroinflammation MetricsFluid Cognition54.4 T-scoreStandard Deviation 6.7
ObeseCognitive Function in Obese and Normal-weight Individuals as Measured by the National Institutes of Health (NIH) Toolbox Cognitive Battery and DBSI Putative Neuroinflammation MetricsCrystallized Cognition53.3 T-scoreStandard Deviation 9
ObeseCognitive Function in Obese and Normal-weight Individuals as Measured by the National Institutes of Health (NIH) Toolbox Cognitive Battery and DBSI Putative Neuroinflammation MetricsFluid Cognition59.3 T-scoreStandard Deviation 7.4
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study. Analyses performed across normal-weight and obese groups.p-value: 0.01Regression, Linear
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study. Analyses performed across normal-weight and obese groups.p-value: 0.1Regression, Linear
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study. Analyses performed across normal-weight and obese groups.p-value: 0.01Regression, Linear
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study. Analyses performed across normal-weight and obese groups.p-value: 0.1Regression, Linear
Post Hoc

Metabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals.

Fasting plasma insulin, a measure of insulin resistance in which higher levels may reflect greater effort to maintain glucose homeostasis, was measured by radioimmunoassay. Normal fasting plasma insulin levels are \< 25 uU/mL.

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Normal-weightMetabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals.5.28 uU/mLStandard Deviation 3.73
ObeseMetabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals.15.62 uU/mLStandard Deviation 10.82
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study.~Analyses performed across normal-weight and obese groups.p-value: >0.46Regression, Linear
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study.~Analyses performed across normal-weight and obese groups.p-value: >0.5Regression, Linear
Post Hoc

Metabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals.

Fasting plasma leptin, a hormone related to adipose tissue mass such that higher levels reflect greater adipose tissue mass, was measured by radioimmunoassay. For body mass index (BMI) in normal-weight (18.5-24.9 kg/m\^2), leptin reference range = 1.8-24.2 ug/L in females and 0.2-7.7 in males. For BMI in individuals with obesity, leptin reference range = 10.6-141 in females and 3.2-135 in males.

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Normal-weightMetabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals.19.9 ug/LStandard Deviation 13.4
ObeseMetabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals.110 ug/LStandard Deviation 49.7
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study.~Analyses performed across normal-weight and obese groups.p-value: 0.62Regression, Linear
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study.~Analyses performed across normal-weight and obese groups.p-value: 0.82Regression, Linear
Post Hoc

Metabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals.

Fasting plasma ghrelin, a hormone related to hunger in which higher levels may signal the stomach is empty and it is time to eat, was measured by radioimmunoassay. Plasma ghrelin levels tend to be lower in people with obesity. There is no established normal range for fasting plasma ghrelin levels as assessed by radioimmunoassay.

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Normal-weightMetabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals.1498.5 pg/mLStandard Deviation 568.6
ObeseMetabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals.914.8 pg/mLStandard Deviation 261.7
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study.~Analyses performed across normal-weight and obese groups.p-value: 0.53Regression, Linear
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study.~Analyses performed across normal-weight and obese groups.p-value: 0.71Regression, Linear
Post Hoc

Metabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals.

Homeostatic measure of insulin resistance (HOMA-IR) where higher scores indicate greater insulin resistance, or diminished maintenance of glucose homeostasis by insulin. HOMA-IR was calculated according to the formula: fasting insulin (uU/L) \* fasting glucose (nmol/L)/22.5 A HOMA-IR score \>2.5 indicates insulin resistance.

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Normal-weightMetabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals.1.21 HOMA-IR scoreStandard Deviation 0.79
ObeseMetabolic Markers in Plasma and Relationships With DBSI Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals.3.47 HOMA-IR scoreStandard Deviation 2.56
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study.~Analyses performed across normal-weight and obese groups.p-value: 0.53Regression, Linear
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study.~Analyses performed across normal-weight and obese groups.p-value: 0.5Regression, Linear
Post Hoc

Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals

Fasting plasma interleukin (IL)-10, an anti-inflammatory cytokine important for immune response. IL-10 was measured using high-sensitive enzyme-linked immuno-absorbent assay (ELISA). Normal reference ranges for IL-10 have not been established and better or worse levels depend on disease state.

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Normal-weightPeripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals1.85 pg/mLStandard Deviation 1.38
ObesePeripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals1.97 pg/mLStandard Deviation 0.75
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study. Analyses performed across normal-weight and obese groups.p-value: 0.09Regression, Linear
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study. Analyses performed across normal-weight and obese groups.p-value: 0.45Regression, Linear
Post Hoc

Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals

Fasting plasma adiponectin, an anti-inflammatory cytokine important for immune response. Adiponectin was measured using radioimmunoassay. Normal reference ranges for adiponectin is 2.5-21.1 ug/mL. Lower levels of adiponectin tend to be associated with worse metabolic health and higher body mass index.

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Normal-weightPeripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals11.3 ug/mLStandard Deviation 5.6
ObesePeripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals10.8 ug/mLStandard Deviation 4.9
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study. Analyses performed across normal-weight and obese groups.p-value: 0.19Regression, Linear
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study.~Analyses performed across normal-weight and obese groups.p-value: 0.52Regression, Linear
Post Hoc

Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals

Fasting plasma tumor necrosis factor (TNF)-alpha, a pro-inflammatory cytokine important for systemic inflammation. TNF-alpha was measured using high-sensitive enzyme-linked immuno-absorbent assay (ELISA). Normal TNF-alpha levels range from non-detectable to 8.1 pg/mL and tend to be higher in people with obesity compared to normal-weight.

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Normal-weightPeripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals0.69 pg/mLStandard Deviation 0.16
ObesePeripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals0.84 pg/mLStandard Deviation 0.16
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study.~Analyses performed across normal-weight and obese groups.p-value: 0.9Regression, Linear
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study.~Analyses performed across normal-weight and obese groups.p-value: 0.87Regression, Linear
Post Hoc

Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals

Fasting plasma monocyte chemoreactant protein (MCP)-1, a pro-inflammatory chemokine important for immune response and inflammation. MCP-1 was measured using enzyme-linked immuno-absorbent assay (ELISA). Normal reference ranges for MCP-1 have not been established but higher levels tend to be associated with higher body mass index.

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Normal-weightPeripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals140.9 pg/mLStandard Deviation 37
ObesePeripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals160.3 pg/mLStandard Deviation 40.1
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study. Analyses performed across normal-weight and obese groups.p-value: 0.26Regression, Linear
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study.~Analyses performed across normal-weight and obese groups.p-value: 0.71Regression, Linear
Post Hoc

Peripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals

Fasting plasma high-sensitive C-reactive protein (CRP), where higher levels may reflect greater low-grade inflammation. High-sensitive CRP was measured using high-sensitive CRP turbidimetry assay. Higher high-sensitive CRP levels may reflect greater risk for cardiovascular disease. Normal range for hs-CRP is usually below 1 mg/L.

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Normal-weightPeripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals1 mg/LStandard Deviation 0.8
ObesePeripheral Inflammation as Measured by Plasma Assays and Relationships With DBSI Putative Neuroinflammation Metrics in White Matter Tracts in Obese and Normal-weight Individuals4.8 mg/LStandard Deviation 3.1
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study. Analyses performed across normal-weight and obese groups.p-value: 0.54Regression, Linear
Comparison: This is a pilot study with a small sample. Power to detect significant results is therefore low in the current study.~Analyses performed across normal-weight and obese groups.p-value: 0.77Regression, Linear

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026